Quetiapine-related weight loss: Report of a rare adverse effect
Journal Title: Journal of Health and Social Sciences - Year 2018, Vol 3, Issue 2
Abstract
Quetiapine is a second-generation antipsychotic that has been reported to be associated with moderate weight gain. Nevertheless, weight loss that is an infrequent adverse effect of quetiapine has been reported in a few cases of patients who were ab initio started on quetiapine or who gained weight during previous antipsychotic treatment but who lost weight when shifted to quetiapine. We report the case of a 28-year old quarry worker being treated for bipolar affective disorder. Due to unbearable muscle rigidity, she was switched from haloperidol to olanzapine. She gained about 26 kg over 12 months. Her repeated complaints about the weight gain and threats to stop all medications if nothing was done led to her being switched over to quetiapine. Within two months of this switch-over, she gained 1 kg before she gradually started losing weight and by the sixth month, she dropped from 85 kg to 67 kg despite eating well. Unsatisfied with the weight loss, she was switched to aripiprazole. Over few months, she gained up to 3 kg. She had remained mentally stable and functional, and also maintained roughly 70 kg over a year. Though weight gain could occur in virtually every antipsychotic, weight loss has been recorded in very few cases. The mechanism by which quetiapine causes weight loss is not certain. Some proposed mechanisms include paradoxical suppression of appetite, induction of deterioration in insulin resistance, induction of hypoglycaemia, as well as mere switching from a high-risk to a low-risk antipsychotic. Our patient had different experiences with three atypical antipsychotics: she gained excessive weight with olanzapine, lost significant weight with quetiapine, and maintained a normal weight with aripiprazole. Weight changes should be monitored on patients taking antipsychotics. Most of the time clinicians are concerned about weight gain but not weight loss. We recommend that clinicians should pay attention to weight loss as well.
Authors and Affiliations
Nicodemus Okwudili K Obayi, David N. Nweke, Edidiong Idio, Darlington Okey, Cletus Ozibo
Keywords
Related Articles
- EP ID EP369912
- DOI 10.19204/2018/qtpn8
- Views 126
- Downloads 0
Role and sensitivity of Positron Emission Tomography with [18F] Fluorodeoxyglucose in diagnosis and follow-up of patients affected by chronic pulmonary aspergillosis (CPA)
Introduction: PET/CT is considered as a powerful tool to diagnose, stage, and monitor patients with a variety of diseases. In this study, we assessed the sensitivity and the degree of agreement between 18F-FDG PET/CT and...
Efficacy of education strategies concerning organ shortage: state-of-the-art and proposals
Introduction: Aim of this study was to review the underlying reasons for organ shortage and the efficacy of current education programs, in order to propose messages to modify socio-psychological feelings to donation. Di...
Promoting cross-culture research on moral decision-making with standardized, culturally-equivalent dilemmas: The 4CONFiDe set
Introduction: Moral dilemmas are a common tool in moral decision-making research. However, they are often hardly comparable across languages and cultures. Here, we propose a methodology to adapt, convert and test moral d...
Gender and HIV/AIDS in Bangladesh: A review
Introduction: The HIV/AIDS epidemic portrays a growing health threat in the world. In Bangladesh, the prevalence rate of HIV/AIDS is not yet high but it is gradually becoming a threat especially for women and young girls...
Terbinafine versus itraconazole: a long-term, randomized, double-blind, clinical trial in chronic pulmonary aspergillosis. A pilote study
Background: The frequency of pulmonary aspergillosis has been increasing for decades. Standard oral treatment is associated with tolerability problems and interactions with commonly used medications. Present data suggest...